Published in Clin Cancer Res on March 26, 2013
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc Natl Acad Sci U S A (2016) 0.82
Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy. Br J Cancer (2015) 0.79
ROCKETSHIP: a flexible and modular software tool for the planning, processing and analysis of dynamic MRI studies. BMC Med Imaging (2015) 0.78
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents. Front Oncol (2016) 0.76
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis. Oncotarget (2016) 0.75
Predicting liver metastasis of gastrointestinal tract cancer by diffusion-weighted imaging of apparent diffusion coefficient values. World J Gastroenterol (2016) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med (2009) 11.51
Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol (2001) 10.39
Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res (2008) 5.67
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res (2010) 3.54
Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med (2000) 3.34
18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med (2009) 3.16
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A (2009) 2.72
Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging (2002) 2.55
Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res (2006) 2.46
Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med (2004) 2.22
Early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.06
Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol (2008) 2.03
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res (2009) 1.89
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology. Cancer Res (2011) 1.72
Multiscale cancer modeling. Annu Rev Biomed Eng (2011) 1.65
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A (2009) 1.63
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res (2006) 1.59
Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res (2007) 1.31
Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol (2008) 1.29
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
A systems approach for tumor pharmacokinetics. PLoS One (2011) 1.27
Dynamic imaging of emerging resistance during cancer therapy. Cancer Res (2006) 1.23
Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med (2009) 1.21
How I treat indolent lymphoma. Blood (2007) 1.20
Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev (2009) 1.19
Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods (2005) 1.13
Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. Magn Reson Med (2010) 1.09
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. Clin Cancer Res (2008) 1.06
Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program (2009) 1.05
Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopy. PLoS One (2012) 1.05
Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI. NMR Biomed (2008) 1.04
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res (2009) 1.00
The measurement of diffusion and perfusion in biological systems using magnetic resonance imaging. Phys Med Biol (2000) 0.98
The integration of quantitative multi-modality imaging data into mathematical models of tumors. Phys Med Biol (2010) 0.96
Incorporation of diffusion-weighted magnetic resonance imaging data into a simple mathematical model of tumor growth. Phys Med Biol (2012) 0.92
Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res (2010) 0.90
Modeling tumor growth and treatment response based on quantitative imaging data. Integr Biol (Camb) (2010) 0.90
FEM-based 3-D tumor growth prediction for kidney tumor. IEEE Trans Biomed Eng (2011) 0.84
Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner. J Nucl Med (2012) 0.84
A robust coregistration method for in vivo studies using a first generation simultaneous PET/MR scanner. Med Phys (2010) 0.81
Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol (2008) 0.80
A multimodal, multidimensional atlas of the C57BL/6J mouse brain. J Anat (2004) 3.28
Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci U S A (2008) 2.50
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Towards effective and rewarding data sharing. Neuroinformatics (2003) 2.24
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood (2011) 2.15
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
Statistical diffusion tensor histology reveals regional dysmyelination effects in the shiverer mouse mutant. Neuroimage (2005) 1.86
Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci U S A (2003) 1.86
Magnetic resonance microscopy: recent advances and applications. Curr Opin Biotechnol (2005) 1.66
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res (2005) 1.54
Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother (2001) 1.51
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2007) 1.50
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol (2008) 1.48
In vivo trans-synaptic tract tracing from the murine striatum and amygdala utilizing manganese enhanced MRI (MEMRI). Magn Reson Med (2003) 1.46
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol (2006) 1.37
Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel (2004) 1.25
Digital three-dimensional atlas of quail development using high-resolution MRI. ScientificWorldJournal (2007) 1.23
Standard atlas space for C57BL/6J neonatal mouse brain. Anat Embryol (Berl) (2005) 1.23
Cerebellar cortical atrophy in experimental autoimmune encephalomyelitis. Neuroimage (2006) 1.23
Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med (2009) 1.20
Role of neuronal activity and kinesin on tract tracing by manganese-enhanced MRI (MEMRI). Neuroimage (2007) 1.20
Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol (2002) 1.20
Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel (2004) 1.18
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med (2013) 1.14
Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother (2007) 1.13
Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother (2008) 1.13
The oligomeric structure of high molecular weight adiponectin. FEBS Lett (2007) 1.13
In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor. Bioconjug Chem (2011) 1.12
Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed (2002) 1.11
Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes alpha7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons. J Neurosci (2009) 1.08
Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res (2007) 1.08
Purkinje cell loss in experimental autoimmune encephalomyelitis. Neuroimage (2009) 1.07
Impact of exercise to improve gait efficiency on activity and participation in older adults with mobility limitations: a randomized controlled trial. Phys Ther (2011) 1.07
Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res (2007) 1.07
Mechanism of age-dependent susceptibility and novel treatment strategy in glutaric acidemia type I. J Clin Invest (2007) 1.07
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. Clin Cancer Res (2008) 1.06
Validation of a measure of smoothness of walking. J Gerontol A Biol Sci Med Sci (2010) 1.05
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res (2003) 1.05
Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Eng Des Sel (2004) 1.05
Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res (2005) 1.03
Multimodal, multidimensional models of mouse brain. Epilepsia (2007) 1.03
Imaging glioma extent with 131I-TM-601. J Nucl Med (2005) 1.03
Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. Bioconjug Chem (2002) 1.02
A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug Chem (2007) 1.02
Towards a Tralfamadorian view of the embryo: multidimensional imaging of development. Curr Opin Neurobiol (2002) 1.01
Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis (2004) 1.00
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res (2009) 1.00
Region-specific myelin pathology in mice lacking the golli products of the myelin basic protein gene. J Neurosci (2005) 0.99
Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res (2004) 0.98
ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel (2010) 0.97
Pathogenesis of human hemangiosarcomas and hemangiomas. Hum Pathol (2013) 0.96
Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem (2006) 0.95
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm (2006) 0.95
Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice. Cancer Biother Radiopharm (2008) 0.95
Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol (2008) 0.94
Use of stance time variability for predicting mobility disability in community-dwelling older persons: a prospective study. J Geriatr Phys Ther (2012) 0.90
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J Immunol (2010) 0.89
Photothermal ablation of pancreatic cancer cells with hybrid iron-oxide core gold-shell nanoparticles. Int J Nanomedicine (2013) 0.89
Myelin deficiencies visualized in vivo: visually evoked potentials and T2-weighted magnetic resonance images of shiverer mutant and wild-type mice. J Neurosci Res (2006) 0.89
Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. Biomaterials (2011) 0.89
Reward circuitry is perturbed in the absence of the serotonin transporter. Neuroimage (2009) 0.88
Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging (2004) 0.88
Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia. Adv Healthc Mater (2013) 0.88
Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET. J Nucl Med (2010) 0.88
Image-guided local delivery strategies enhance therapeutic nanoparticle uptake in solid tumors. ACS Nano (2013) 0.87
The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol (2005) 0.87
Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions. Bioconjug Chem (2002) 0.87
T(2)-weighted microMRI and evoked potential of the visual system measurements during the development of hypomyelinated transgenic mice. Neurochem Res (2006) 0.87
Altered neurocircuitry in the dopamine transporter knockout mouse brain. PLoS One (2010) 0.86
Deficits in axonal transport in hippocampal-based circuitry and the visual pathway in APP knock-out animals witnessed by manganese enhanced MRI. Neuroimage (2012) 0.85
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel (2012) 0.85
Magnetic resonance imaging of functional anatomy: use for small animal epilepsy models. Epilepsia (2007) 0.84
Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner. J Nucl Med (2012) 0.84
Quantitative pharmacologic MRI: mapping the cerebral blood volume response to cocaine in dopamine transporter knockout mice. Neuroimage (2010) 0.84
Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation. Nanomedicine (Lond) (2013) 0.84
A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother Radiopharm (2010) 0.83
Live imaging of neuronal connections by magnetic resonance: Robust transport in the hippocampal-septal memory circuit in a mouse model of Down syndrome. Neuroimage (2007) 0.83
Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging. Bioconjug Chem (2011) 0.82
Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting. Peptides (2003) 0.82
Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjug Chem (2005) 0.82
A robust coregistration method for in vivo studies using a first generation simultaneous PET/MR scanner. Med Phys (2010) 0.81
High resolution MRI for non-invasive mouse lymph node mapping. J Immunol Methods (2013) 0.81
MRI in developmental biology and the construction of developmental atlases. Cold Spring Harb Protoc (2011) 0.81
Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice. Bioconjug Chem (2013) 0.80
Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49. Biochem Biophys Res Commun (2005) 0.79
Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity. Bioprocess Int (2010) 0.79
The two types of correction of absorbed dose estimates for internal emitters. Cancer (2002) 0.79
Increased anatomical detail by in vitro MR microscopy with a modified Golgi impregnation method. Magn Reson Med (2010) 0.79